Education
About Us
Working with TipRanks
Follow Us
Cognition Therapeutics (CGTX)
NASDAQ:CGTX
Total Valuation
Cognition Therapeutics has a market cap or net worth of $18.67M. The enterprise value is -$5.53M.
Market Cap$18.67M
Enterprise Value-$5.53M
Share Statistics
Cognition Therapeutics has 61,993,046 shares outstanding. The number of shares has decreased by -2.65% in one year.
Shares Outstanding61,993,046
Owned by Insiders22.36%
Owned by Institutions0.11%
Financial Efficiency
Cognition Therapeutics’s return on equity (ROE) is -1.81 and return on invested capital (ROIC) is -279.83%.
Return on Equity (ROE)-1.81
Return on Assets (ROA)-1.12
Return on Invested Capital (ROIC)-279.83%
Return on Capital Employed (ROCE)-2.83
Revenue Per Employee0.00
Profits Per Employee-1.36M
Employee Count25
Asset Turnover0.00
Inventory Turnover0.00
Valuation Ratios
The current PE Ratio of Cognition Therapeutics is -0.82. Cognition Therapeutics’s PEG ratio is -0.07.
PE Ratio-0.82
PS Ratio0.00
PB Ratio0.75
Price to Fair Value1.49
Price to FCF-0.66
Price to Operating Cash Flow-0.49
PEG Ratio-0.07
Income Statement
In the last 12 months, Cognition Therapeutics had revenue of 0.00 and earned -33.97M in profits. Earnings per share was -0.86.
Revenue0.00
Gross Profit0.00
Operating Income-53.97M
Pretax Income-33.97M
Net Income-33.97M
EBITDA-33.68M
Earnings Per Share (EPS)-0.86
Cash Flow
In the last 12 months, operating cash flow was -28.47M and capital expenditures -1.00K, giving a free cash flow of -28.48M billion.
Operating Cash Flow-28.47M
Free Cash Flow-28.48M
Free Cash Flow per Share-0.46
Dividends & Yields
Cognition Therapeutics pays an annual dividend of ―, resulting in a dividend yield of ―
Dividend Per Share―
Dividend Yield―
Payout RatioN/A
Free Cash Flow Yield―
Earnings Yield―
Stock Price Statistics
Beta1.90
52-Week Price Change-84.62%
50-Day Moving Average0.41
200-Day Moving Average0.57
Relative Strength Index (RSI)31.38
Average Volume (3m)777.74K
Important Dates
Cognition Therapeutics upcoming earnings date is Aug 12, 2025, TBA Not Confirmed.
Last Earnings DateMay 7, 2025
Next Earnings DateAug 12, 2025
Ex-Dividend Date―
Financial Position
Cognition Therapeutics as a current ratio of 2.65, with Debt / Equity ratio of 4.34%
Current Ratio2.65
Quick Ratio2.65
Debt to Market Cap<0.01
Net Debt to EBITDA0.72
Interest Coverage Ratio0.00
Taxes
In the past 12 months, Cognition Therapeutics has paid 0.00 in taxes.
Income Tax0.00
Effective Tax Rate0.00
Enterprise Valuation
Cognition Therapeutics EV to EBITDA ratio is -0.11, with an EV/FCF ratio of -0.13.
EV to Sales0.00
EV to EBITDA-0.11
EV to Free Cash Flow-0.13
EV to Operating Cash Flow-0.13
Balance Sheet
Cognition Therapeutics has $25.01M in cash and marketable securities with $814.00K in debt, giving a net cash position of -$24.20M billion.
Cash & Marketable Securities$25.01M
Total Debt$814.00K
Net Cash-$24.20M
Net Cash Per Share-$0.39
Tangible Book Value Per Share$0.47
Margins
Gross margin is 0.00%, with operating margin of 0.00%, and net profit margin of 0.00%.
Gross Margin0.00%
Operating Margin0.00%
Pretax Margin0.00%
Net Profit Margin0.00%
EBITDA Margin0.00%
EBIT Margin0.00%
Analyst Forecast
The average price target for Cognition Therapeutics is $6.67, which is 11.43% higher than the current price. The consensus rating is Strong Buy
Price Target$6.67
Price Target Upside2123.33% Upside
Analyst ConsensusStrong Buy
Analyst Count3
Revenue Growth Forecast―
EPS Growth Forecast-0.38%